Sivextro (tedizolid) / Merck (MSD), Nabriva Therap - LARVOL DELTA

A Persistent Problem: Mycobacterium abscessus Infection of an Orthopedic Device after Trauma. (PubMed, Mil Med) - "After a multitude of surgeries, including orthopedic hardware removal from the forearm, and concurrent antibiotic therapy of amikacin, imipenem, tedizolid, and omadacycline, the patient was deemed medically cleared of her infection. This has implications for both civilian and military battlefield-related trauma infections. This case serves as an example of successful multi-disciplinary management through appropriately aggressive surgery and tailored antibiotic therapy."

Journal • Infectious Disease • Musculoskeletal Diseases • Nontuberculous Mycobacterial Disease • Orthopedics

Hybrid Antibiotics Targeting the Bacterial Ribosome. (PubMed, ACS Cent Sci) - "Here we describe the design, synthesis, and microbiological and structural characterization of hybrid antibiotics of azithromycin, tedizolid, and chloramphenicol that span the peptidyltransferase center (PTC) and nascent peptide exit tunnel (NPET) in the bacterial ribosome. These results extend our understanding of ribosome inhibition and provide a pipeline for the rational design of dual-action antibiotics that target the ribosome. In a broader context, this work offers a framework for developing bifunctional inhibitors that engage adjacent binding sites by means of a rational cycle of synthetic optimization, biological evaluation, and structural characterization."

Journal • Infectious Disease

How to use novel antimicrobials beyond official indications: an expert consensus. (PubMed, JAC Antimicrob Resist) - "The process comprised three survey rounds evaluating off-label uses of eight drugs: ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, ceftaroline, ceftobiprole, dalbavancin, tedizolid, and isavuconazole. The guidance prioritizes targeted treatment over empirical use, aligning with international ASP principles and WHO recommendations. These results provide a regional reference to optimize ASP initiatives focus on new antibiotic use while minimizing ecological impact and resistance development."

Journal • Cardiovascular • Critical care • Infectious Disease

Multidrug-resistant extra-pulmonary tuberculosis in a hemodyalisis patient treated with bedaquiline and tedizolid. A case report and a literature rewiew. (PubMed, Farm Hosp) - No abstract available

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

In Vitro Activity of Sulfamethoxazole-Trimethoprim, Amikacin, Oxazolidinones, Fluoroquinolones and Fidaxomicin against Isolates of Nocardia. (PubMed, ACS Omega) - "This study evaluates the in vitro activity of common and potential antimicrobials, including Trimethoprim-sulfamethoxazole, Amikacin, Oxazolidinones (Linezolid, Tedizolid, Contezolid), Fluoroquinolones (Moxifloxacin, Levofloxacin, Sitafloxacin), Rifampicin, and Fidaxomicin against 51 clinical Nocardia isolates. These findings highlight the need for tailored treatment strategies based on species-specific susceptibility and resistance profiles and suggest Fidaxomicin and Sitafloxacin as promising options. Further clinical validation is warranted to optimize therapeutic outcomes."

Journal • Preclinical • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Therapeutic options and prognostic risk factors in diabetic foot osteomyelitis: a narrative review. (PubMed, Int J Surg) - "Emerging antimicrobial agents such as dalbavancin, tedizolid, and novel cephalosporins, alongside bacteriophage therapy and immunomodulatory strategies like granulocyte colony-stimulating factor (G-CSF), show promise in improving infection management. Prognosis heavily depends on glycemic control, renal function, immune status, and cardiovascular health. Comprehensive multidisciplinary management is crucial to improving patient outcomes, reducing amputations, and enhancing quality of life."

Journal • Cardiovascular • Diabetes • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

Anti-IFN-gamma Autoantibodies In An Adult Patient With Disseminated Mycobacterium Abscessus Infection (ACAAI 2025) - "Supraclavicular lymph node biopsy showed inflammation with sclerosis, and cultures grew M. abscessus , prompting initiation of amikacin, meropenem, and omadacycline. Seven months later, patient had radiographic and clinical improvement and was transitioned to oral omadacycline and tedizolid for minimum twelve-month course...Identification of anti-IFN-γ autoantibodies is critical given the role of immunomodulatory therapies including rituximab and IFN-γ in patients with antimicrobial-refractory infections. Most recently, CAAR T cell therapy has shown promise in averting anti-IFN-γ autoantibody-related infections by targeting self-reactive B cells."

Clinical • Asthma • Cough • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammation • Influenza • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Tetanus • Tuberculosis • CD4 • CSF2 • IFNG

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis. (PubMed, BMC Infect Dis) - "Our findings indicate that omadacycline is a promising treatment option for ABSSSI, demonstrating efficacy that is comparable to or potentially superior to many other anti-MRSA agents, along with a favorable safety profile. However, these results should be interpreted with caution due to the study's inherent limitations."

Clinical • Journal • Retrospective data • Review • Infectious Disease

Diphtheria-like Pseudomembranous Corynebacterium striatum Chronic Infection of Left Ventricular Assist Device Driveline Bridged to Heart Transplantation with Dalbavancin Treatment. (PubMed, Reports (MDPI)) - "The patient experienced recurrent episodes of C. striatum bacteremia despite multiple courses of targeted antibiotic therapy, including vancomycin, linezolid, tedizolid, teicoplanin, and dalbavancin. Histopathological analysis revealed necrotic elements and Gram-positive organisms consistent with pseudomembranous inflammation. The case describes the diagnosis and treatment of this rare infection, highlighting the pathogenic potential of C. striatum, its role in device-related infections, and the histopathological evidence of pseudomembrane formation."

Journal • Cardiovascular • Infectious Disease • Inflammation • Transplantation

Efficacy and safety of tedizolid in the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis of randomised controlled trials. (PubMed, Clin Microbiol Infect) - "Tedizolid demonstrated non-inferior efficacy compared to standard treatments for ABSSSIs and may offer advantages in safety, especially in haematological patients. Its once-daily dosing and shorter regimen support its use as a therapeutic alternative in selected patients."

Journal • Retrospective data • Review • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease • Neutropenia • Thrombocytopenia

LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring. (PubMed, Drug Des Devel Ther) - "Detection was performed via positive electrospray ionization (ESI+) in multiple reaction monitoring (MRM) mode, targeting transitions: m/z 338.14→162.8 (linezolid); m/z 371→343.1 (tedizolid) and m/z 409.15→269.14 (contezolid), with voriconazole-d3 as the internal standard. This method has been successfully applied to monitor the concentrations of both drugs during the transition between linezolid and contezolid therapy. This validated LC-MS/MS method enables the simultaneous determination of linezolid, tedizolid, and contezolid in human plasma, rendering it promising for pharmacokinetic studies and TDM, and contributing to optimized patient care in complex therapeutic scenarios."

Journal • Infectious Disease

Effect of antibiotics on Kupffer cell immunometabolism relative to intracellular killing of S. aureus using NAD(P)H fluorescence lifetime imaging. (PubMed, mBio) - "We investigated the immunometabolic effects of antistaphylococcal antibiotics (vancomycin, ceftobiprole, daptomycin, and tedizolid) on KCs relative to clearance of intracellular SA through gene expression analysis and optical metabolic imaging using fluorescence lifetime imaging microscopy. Vancomycin, however, did not affect KC metabolism and was unable to control bacterial growth inside the cells. These findings suggest that choosing antibiotics based on direct antimicrobial activity as well as indirect effects on host immune function could improve treatment outcomes for patients with S. aureus bloodstream infection."

Journal • Infectious Disease • Inflammation • Septic Shock

Viral Load to Overload: A Multisystem Meltdown in Motion (ASA 2025) - "Required several weeks of ECMO before transition to Trach placement for long term ventilation and discharge to LTAC. Course also complicated by bronchopleural fistula treated with Endobronchial valve placement & serotonin syndrome from Linezolid/Fluoxetine/Trazadone, requiring transition to Tedizolid/Doxycycline with cessation of Fluoxetine/Trazadone."

Infectious Disease • Influenza • Pneumonia • Respiratory Diseases • Septic Shock

Linezolid-related Optic Nerve Disorders: Insight From a Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System. (PubMed, Open Forum Infect Dis) - "Data regarding the usage and toxicity features of linezolid and those of tedizolid, a related agent with a potentially improved safety profile, are limited...Among oxazolidinones, a signal for optic nerve disorders was detected exclusively for linezolid. Clinicians should ensure regular ophthalmologic monitoring during linezolid treatment, particularly in younger patients and those receiving high cumulative doses."

Adverse events • Clinical • Journal • Infectious Disease • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

A strategy to re-sensitise drug-resistant Gram-positive bacteria to oxazolidinone-class antibiotics. (PubMed, EBioMedicine) - "As both agents have excellent safety profiles, such clinical investigation may immediately be contemplated in humans. Translationally, scientists benefit from strategy by simultaneously achieving greater efficacy (>500-fold re-sensitisation) and higher safety (prodrug-based and microbiome-friendly strategy especially when active form may be toxic)."

Journal • Infectious Disease • Ocular Infections

When Should You Consider Tedizolid? (IDWeek 2025) - No abstract available

Infectious Disease

171 - New Antibiotics, Untapped Potential: Exploring the Underuse of Recently Approved Agents (IDWeek 2025) - "Learning Objectives: At the conclusion of this session, participants will be able to: recognize situations where new antimicrobial agents may optimize clinical outcomes; describe the place in therapy of imipenem-relebactam relative to other novel beta-lactam/beta-lactamase inhibitors; select clinical situations where tedizolid may be considered over linezolid; compare and contrast omadacycline and eravacycline for infections beyond non-tuberculous mycobacteria."

Infectious Disease • Nontuberculous Mycobacterial Disease

Tedizolid Neuropathies (clinicaltrials.gov) - P=N/A | N=5 | Completed | Sponsor: Hospices Civils de Lyon

New trial • Pain

Gram-positive pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23). (PubMed, J Antimicrob Chemother) - "The CANWARD surveillance study has provided 17 years of reference antimicrobial susceptibility testing data on Gram-positive pathogens."

Journal • Critical care • Infectious Disease • Pneumococcal Infections • Pneumonia

Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series. (PubMed, J Antimicrob Chemother) - "Prolonged used of tedizolid may be associated with peripheral neurologic toxicity, which should be monitored in at-risk patients."

Journal • Diabetes • Diabetic Nephropathy • Diabetic Neuropathy • Hematological Disorders • Infectious Disease • Metabolic Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain • Renal Disease

Evaluation of Bedaquiline in Treatment of Nontuberculous Mycobacterial Infections in Transplant Patients (WTC 2025) - "Commonly co-prescribed agents included tedizolid, omadacycline, and tigecycline. Azithromycin was used for non-abscessus isolates... Bedaquline was well tolerated in this cohort of SOT patients with NTM infection, with no documented adverse effects requiring discontinuation of the medication. Furthermore, the majority of patients achieved resolution of infection with comparatively low rate of recurrence."

Clinical • Nontuberculous mycobacteria • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases • Solid Organ Transplantation • Transplantation

Insufficient cerebrospinal fluid penetration of tedizolid: a case report. (PubMed, JAC Antimicrob Resist) - "A brief review of the literature corroborated the observation that CSF penetration of tedizolid was markedly lower than that of linezolid. Considering the consistently low CSF concentrations of tedizolid, linezolid remains the preferred agent for the treatment of CNS infections."

Journal • CNS Disorders • Infectious Disease • Inflammation

High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid. (PubMed, J Antimicrob Chemother) - "Salivary TDM is a promising alternative to conventional serum sampling for linezolid but is less feasible for tedizolid."

Journal

Establishing Structure-Activity Relationships in Heterogeneous Catalysis of Three-Component Organic Coupling Reactions by Lewis Acidic Metal Sites and Polar Moieties. (PubMed, ACS Appl Mater Interfaces) - "A wide spectrum of substrates with diverse electronic, steric, and polarizing effects is tested to obtain bioactive precursors, particularly tedizolid and delpazolid, achieving high conversion rates (65-94%) and turnover numbers. The postcatalysis analysis of both Co-bpaipa and Ni-bpaipa demonstrates their structural stability and nonleachability, even after multiple catalytic runs."

Heterogeneity • Journal

In Vitro Activity of Novel Antibiotics Against Corynebacterium spp. Clinical Isolates Responsible for Difficult-to-Treat Infections. (PubMed, Microb Drug Resist) - "The activity of ceftaroline (MIC90 >2 mg/L), ceftobiprole (MIC90 >8 mg/L), and delafloxacin (MIC90 >1 mg/L) was limited. By contrast, other molecules tested showed higher activity with low MIC90 values: linezolid (MIC90 ≤0.5 mg/L), tedizolid (MIC90 = 0.12 mg/L), dalbavancin (MIC90 = 0.12 mg/L), tigecycline (MIC90 = 0.12 mg/L), eravacycline (MIC90 = 0.06 mg/L), and omadacycline (MIC90 = 0.5 mg/L). One C. striatum strain exhibited a high level of daptomycin resistance after antibiotic exposure (MIC >16 mg/L). The in vitro activity of most of these novel antibiotics is excellent against Corynebacterium clinical isolates. They could represent a real alternative for treating DTT infections due to Corynebacterium spp."

Journal • Preclinical • Infectious Disease